Evidence map›Paper›PMID 20890105›Full record

ArticleCell cycle (Georgetown, Tex.)2010

Evolutionary dynamics of two related malignant plasma cell lines.

David Dingli, Bonnie K Arendt, Zeljko Bajzer, Diane F Jelinek

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

David DingliDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. dingli.david@mayo.edu
Bonnie K Arendt
Zeljko Bajzer
Diane F Jelinek
Mayo Clinic · USMayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

TISSUE BANK AND CLINICAL/LABORATORY DATABASEP01CA062242 · NCI · MAYO CLINIC ROCHESTER · PI THERNEAU, TERRY M · 1994 to 2009
$12.9M
NCI NIH HHS CA062242
6 · The paper itself

Abstract

Cancer is the consequence of sequential acquisition of mutations within somatic cells. Mutations alter the relative reproductive fitness of cells, enabling the population to evolve in time as a consequence of selection. Cancer therapy itself can select for or against specific subclones. Given the large population of tumor cells, subclones inevitably emerge and their fate will depend on the evolutionary dynamics that define the interactions between such clones. Using a combination of in vitro studies and mathematical modeling, we describe the dynamic behavior of two cell lines isolated from the same patient at different time points of disease progression and show how the two clones relate to one another. We provide evidence that the two clones coexisted at the time of initial presentation. The dominant clone presented with biopsy proven cardiac AL amyloidosis. Initial therapy selected for the second clone that expanded leading to a change in the diagnosis to multiple myeloma. The evolutionary dynamics relating the two cell lines are discussed and a hypothesis is generated in regard to the mechanism of one of the phenotypic characteristics that is shared by these two cell lines.

Indexed as

Evolution, MolecularMutationAmyloidosisAntineoplastic Agents, AlkylatingCell Line, TumorDexamethasoneDisease ProgressionHematopoietic Stem Cell TransplantationHumansInterleukin-6MelphalanMultiple MyelomaAntineoplastic Agents, AlkylatingDexamethasoneInterleukin-6Melphalan

Identifiers

PMID20890105
PMCPMC3047803
OpenAlexW1974006802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.